Company Filing History:
2 out of 66 
1 out of 36 
1 out of 1 Years Active: 2019-2025
Title: The Innovations of Thorsten Litzenberger: Pioneering Cancer Research
Introduction
Thorsten Litzenberger, an innovative inventor based in Olsbrücken, Germany, has made significant contributions to the field of cancer therapy. With a total of two patents to his name, his groundbreaking work primarily focuses on the identification and application of tumor antigens to enhance cancer treatment, particularly for breast cancer.
Latest Patents
Thorsten's latest patents revolve around tumor antigens for determining cancer therapy. His innovative approach targets breast cancer, especially the aggressive triple-negative subtype. The inventions provide critical methods and means that utilize specific sets of tumor antigens, aiming to improve the efficacy and precision of cancer treatments. These patents represent a leap forward in personalized medicine, tailoring interventions to individual tumor profiles.
Career Highlights
Throughout his career, Thorsten has worked at notable organizations that emphasize cutting-edge cancer research. Notably, he was part of BioNTech AG, a leading biotechnology company known for its pioneering work in mRNA therapeutics. Additionally, he contributed to the efforts at Translational Oncology at the University Medical Center of Mainz, an institution dedicated to advancing cancer therapies through innovative research.
Collaborations
Thorsten Litzenberger has collaborated with prominent figures in the field, including Ugur Sahin and Claudia Paret. Their collective expertise and shared vision for cancer treatment reflect the importance of teamwork in advancing medical research and developing effective therapies for patients facing cancer.
Conclusion
Thorsten Litzenberger's work exemplifies the intersection of innovation and medicine. His patents and collaborations stem from a deep commitment to improving cancer therapies, particularly for those diagnosed with challenging forms of the disease. His contributions not only enhance our understanding of tumor biology but also pave the way for more targeted, effective treatment options in the future.